Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-MSC in Post-COVID-19 Pulmonary Compromise
NCT04909892Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of COVI-MSC in post-COVID-19 condition (PCC), sponsored by Sorrento Therapeutics. Planned start Aug 2021; status: withdrawn.
02
Drugs
COVI-MSC
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT04909892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04909892.